---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-058351"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:23:37.215645+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Eloxx Q1 net loss $11.6M; CF award up to $15.9M; cash into Q2 2023

## Summary
- Net loss $11.6M ($0.13/sh) vs $8.7M ($0.22/sh) in Q1 2021; R&D $7.9M, G&A $3.1M.
- CF Foundation award up to $15.9M for ELX-02; Phase 2 CF topline results expected end H1 2022.
- Expanded ELX-02 development to Alport syndrome; Phase 2 proof-of-concept trial for nonsense mutations starts H2 2022.
- Cash $39.8M sufficient into Q2 2023; ZKN-013 IND for RDEB planned H2 2022.

## SEC filing metadata
- accession: 0001104659-22-058351
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465922058351/0001104659-22-058351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465922058351/tm2215074d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-058351
- JSON: https://secwatch.observer/filing/0001104659-22-058351.json
- Plain text: https://secwatch.observer/filing/0001104659-22-058351.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.